Abstract:Objective This study utilized the stimulated thyroglobulin (sTg) to thyroid stimulating hormone (TSH) ratio to predict the long-term efficacy of 131 I therapy in patients with moderate-to-high-risk differentiated thyroid cancer (DTC). Methods This study retrospectively analyzed 960 DTC patients with a median follow-up time of 30 months (6–92 months). The median age was 44 years. All patients underwent total thyroidectomy, lymph node dissection, and at least one 131 I therapy. Patients were subjected to a final efficacy evaluation according to American Thyroid Association’s 2015 guidelines. Patients were grouped according to their TSH levels before the initial 131 I therapy and the final efficacy evaluation, and factors influencing TSH levels and final efficacy were analyzed. Construction of nomograms using independent risk factors affecting long-term outcomes. The cut-offs of sTg and sTg/TSH ratios were calculated for different long-term outcomes. Progression-free survival (PFS) of patients was analyzed by making Kaplan-Meier survival according to the cut-offs of sTg and sTg/TSH ratio. Results TSH (mU/L) levels were more concentrated at 60–90 in females (71.5%) and 30–60 in males (39.0%), while patients with younger age, more lymph node metastases, shorter time interval between surgery and the first 131 I therapy, and lower dose of levothyroxine sodium taken prior to the first 131 I therapy would have higher TSH levels (All P < 0.05).Patients who are male, have primary tumor involvement of the strap muscles, lymph node metastasis, distant metastasis, and higher sTg and sTg/TSH are more likely to have poor long-term outcomes (All P < 0.05).The cut-offs of sTg and sTg/TSH for long-term efficacy were 7.515 and 0.095. STg, sTg/TSH, tumor size, lymph node metastasis, and distant metastasis were shown to be independent risk factors for long-term efficacy. The mean PFSs were longer for patients who had sTg/TSH ≤ 0.095 and/or sTg≤7.515 ug/L. Conclusions For patients with moderate-to-high-risk DTC, when sTg>7.515 ug/L and/or sTg/TSH > 0.095 before the first 131 I therapy, patients are more likely to have a poor long-term efficacy after full 131 I therapy. This means that this group of patients may require further surgical treatment or targeted drug therapy after 131 I therapy.

The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of <SUP>131</SUP>I Treatment in DTC Patients

Stimulating Thyroglobulin to TSH Ratio Predict Long-Term Efficacy of 131 I Therapy in Patients with Differentiated Thyroid Cancer after Total Thyroidectomy: a Retrospective Study

Predictive value of the stimulated thyroglobulin before and after 131I therapy for curative effect in patients with papillary thyroid carcinoma

Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study

The study of influence factors on 131I treatment of differentiated thyroid carcinoma with lymph node metastases

Predictive Value of Preablation Stimulated Thyroglobulin and Thyroglobulin/thyroid-Stimulating Hormone Ratio in Differentiated Thyroid Cancer.

Tg Levels in Differentiated Thyroid Cancer Patients with Intermediate or Low Risk of Recurrence after 131I Therapy

In Patients with Low- to Intermediate-Risk Thyroid Cancer, A Preablative Thyrotropin Level of 30 Mu Iu/Ml is Not Adequate to Achieve Better Response to I-131 Therapy

Efficacy analysis of 131I therapy and predictive value of preablation stimulated thyroglobulin for lung metastases from differentiated thyroid cancer

Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study

In Patients with Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 Μiu/ml is Not Adequate to Achieve Better Response to 131I Therapy.

The impact of thyroglobulin antibody on efficacy of131I ablation in patients with papillary thyroid carcinoma

Efficacy Evaluation and Influencing Factor Analysis of Postoperative 131I for the Treatment of Primary Hyperthyroidism Combined with Differentiated Thyroid Cancer (Dtc)-a Retrospective Cohort Study.

TSH 30 mU/L may not be necessary for successful <SUP>131</SUP>I remnant ablation in patients with differentiated thyroid cancer

The Role of Preablative Stimulated Thyroglobulin in Guiding Risk Estimation and Therapeutic Decisions of Differentiated Thyroid Carcinoma

Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer

Predictive value of thyrotropin receptor in radioactive iodine therapy of differentiated thyroid carcinoma

Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study

Therapeutic Effect and Influencing Factor in 131I Treated Differentiated Thyroid Cancer Patients with Remote Metastases

Quantitive Study about Influence of 131Ⅰ Diagnostic Dose on Uptake of 131Ⅰ for Differentiated Thyroid Carcinoma

Sufficiency of a Single Negative Thyroglobulin Standard for Judging the Success of Ablation in Low- and Intermediate-risk Differentiated Thyroid Cancer: A Retrospective Study